Clinical significance and prognostic analysis of TILs and PD-L1 expression in non-small cell lung cancer

Since the US FDA approved immunotherapy in 2015, immuno-oncology has completely changed the treatment of non-small cell lung cancer (NSCLC) and has become a new and effective treatment.However, the overall effectiveness of immunotherapy is only 20% to 30%, only a small number of patients can benefit from it, and it also produces a series of toxic side effects.Studies have shown that tumor-infiltrating lymphocytes (TILs) are associated with a variety of tumor outcomes, especially in lung cancer.Therefore, there is still room to improve outcomes for patients with non-small cell lung cancer.Finding efficient and accurate biomarkers to predict and screen cancer patients with good efficacy for PD-1/PD-L1 inhibitor therapy has become an important clinical research hotspot and urgent need.The purpose of this review is to elucidate the clinical significance of TILs and PD-L1 expression in NSCLC and its correlation with prognosis, and to provide clinical reference for patients receiving immunotherapy.